Nkarta(NKTX) - 2023 Q4 - Annual Results

Exhibit 99.1 Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights SOUTH SAN FRANCISCO, Calif., March 21, 2024 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2023. "Patients with severe autoimmune diseases deserve novel, effective treatments," noted Paul J. Hastings, President and CEO of Nkarta. "Recent ...